Background: Breast cancer is a complex, heterogeneous disease and one of the most common malignancies in women worldwide. The efficacy of chemotherapy as an important breast cancer treatment option has been severely limited because of the inherent or acquired resistance of cancer cells. The molecular chaperone heat shock protein 90 (HSP90) upregulated in response to cellular stress is required for functions such as conformational maturation, activation and stability in more than 200 client proteins, mostly of the signaling type. In this study, the expression of HSP90 isoforms including HSP90α and HSP90 in breast cancer cell lines before and after treatment with doxorubicin (DOX) was assessed.
Introduction
Breast cancer is a complex and heterogeneous disease and one of the most common malignancies in women worldwide. A total of 234,190 new breast cancer cases and 40,730 cancer deaths were anticipated to occur in the United States in 2015 [1, 2] . Such a high prevalence reflects the limited efficacy of chemotherapy, which can be primarily attributed to the development of resistance to chemotherapeutic drugs. Chemotherapeutic drugs such as doxorubicin (DOX) are generally used to treat a variety of malignancies such as breast cancer but the drug resistance acquired by cancer cells can lead to treatment failure as surviving cancer cells become refractory to treatment and contribute to recurring and increased metastatic activity [3] [4] [5] [6] . There is currently an inadequate understanding of the molecular and cellular mechanisms that govern breast cancer and the mechanisms underlying the chemotherapy resistance. The heat shock proteins assist other proteins under normal and stress conditions to manage several actions including correct folding, assembly, intracellular localization, secretion, regulation and degradation [7] . Among these proteins, the molecular chaperone HSP90 with more than 200 target proteins has gained interest as a promising anti-cancer drug target, as many of these target proteins play an important role in disrupted pathways involved in different types of cancer [8] . Two highly elevated vertebrate HSP90 isoforms, namely HSP90α and HSP90 , are encoded by human genes [9, 10] . The breast cancer cell lines can be representative of the key genetic and transcriptional features involved in the breast tumors [11] [12] [13] [14] . The pathobiology, screening and therapeutic features of the breast cancer can be examined using these cell lines [15, 16] , which have several advantages such as the relative ease of culturing, the possibility of being pharmacologically functional assays, and purity of cancerous cells or non-contaminated stromal cell [14] . The present study aimed to investigate two different breast cancer cell lines, MCF-7 and MDA-MB-231. MCF-7 cells are estrogen receptor (ER)-positive cells that have been widely used to study estrogen-related pathways and the development of anti-hormonal therapies for breast cancer [17] [18] [19] . The MDA-MB231 cell line is ER-negative and resembles the recently characterized claudin-low tumor subtype of breast cancer [20, 21] . Additionally, the MCF-7 originates from metastatic sites in adenocarcinoma, as a tumorigenic adherent breast epithelial cell line, whereas the MDA-MB-231 cell line is a tumorigenic metastatic breast cell line [22] .
Studies are continuously conducted worldwide to identify the critical factors involved in cancer resistance to chemotherapy. To supplement existing efforts, the current study was carried out to compare the expression of HSP90α and HSP90 in MDA-MB-231 and MCF-7 cells after treatment with DOX.
Materials and Methods
Antibodies against HSP90 (sc-1057) and HSP90α (sc-8262) and HRP secondary antibodies (sc-2354) and FITC-conjugated secondary antibodies (sc-2988) were obtained from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Inc., Texas and Santa Cruz Biotechnology, Inc., California, respectively). A beta actin antibody (ab8502) was obtained from United States Abcam. DOX (D1515) and MTT powder (M2128) were purchased from Germany Sigma.
Breast cancer cell lines
The MDA-MB-231 and MCF-7 cell lines (prepared from Pasture Institute of Iran) were initially cultured in RPMI 1640 medium in the presence of 10% FBS and 100 U/ml of penicillin/streptomycin. The incubation was performed at 37°C with 5% CO 2 and humidity.
MTT assay
A colorimetric assay with tetrazolium salt was used to assess the anti-proliferative effects of DOX. The breast cancer cells were seeded at 10,000 cells/well in 96-well plates and allowed to grow for 48 h. The cells were then treated with different concentrations of DOX for 24 h, after which each well was poured by 10 μl of MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] and 5 mg/ml in PBS (phosphate buffered saline) solution, and incubation was done at 37°C for 4 hours. After dissolving the formazan crystals in the DMSO, a microplate reader was used to read the absorbance of the wells at 570 nm. Finally, the data were reported as means ± standard deviation for all experiments with more than three replicates, and statistically analyzed using SPSS software. The linear regression analysis was applied to estimate the half-maximal inhibitory concentrations (IC 50 ) from the in vitro dose-response curves.
Western blotting
The MCF-7 and MDA-MB-231 cells were cultured in 100 mm plates and treated with DOX (0, 0.2, 5 and 10 μM) for 24 h. The cells were rinsed with cold PBS once and lysed with 500 μl of RIPA buffer (50 mM of Tris, pH=8, 150 mM of NaCl, 0.1% SDS, 0.5% Na deoxycholic acid, 1% NP-40 or IGEPAL, 10 g/ml of aprotinin and 10 g/ml of leupeptin). A 25 G 5/8 needle was employed to break the cells whose extract was centrifuged for 30 min at 14,000 rpm at 4˚C. Then, the resulting supernatant was stored at -20˚C until testing. Bradford method was followed to obtain the protein concentration. In addition, 24 μg proteins per well were electrophoresed using SDS polyacrylamide gels, and were then delivered onto a nitrocellulose membrane with a semi-dry gel transfer apparatus. Next, 5% milk in PBST (PBS with 0.05% Tween 20) was used to block the membranes at room temperature for 1-2 hours, and subsequently was incubated in the presence of a primary antibody against HSP90 or -actin at 4˚C overnight. After that, the membranes were washed with PBST for 10 min. The incubation was performed for an hour with the HRP-labeled secondary antibody in 5% milk in PBST. The washing was continued with PBST for 20-30 min, and then the membranes were treated with chemiluminescence reagents and exposed to Kodak film.
Immunofluorescence
The study cell lines after culturing on coverslips within cell culture plates were treated at 0, 0.2, 5, 10 μM concentrations of DOX and incubated for 24 hours. In the next step, the cells following washing by PBS were fixed with 4% paraformaldehyde/PBS at ambient temperature for 15 min. The cells were rewashed and exposed to immunofluorescence staining with a polyclonal primary antibody against HSP90 and HSP90 followed by the corresponding FITC-conjugated secondary antibody. The stained cells were examined using a fluorescence microscope.
Statistical analysis
The data obtained from the MTT assay were plotted. Also, linear charts were drawn; and the average, standard deviation, standard error, and IC 50 values were calculated. Total Lab software was used for the densitometry of the bands. All values were presented as mean ± SEM from three independent experiments, and statistically significant differences were determined among various groups by ANOVA and Tukey posttest using SPSS 12.0 statistical software.
Results
The cytotoxic effects of DOX on the proliferation of the MCF-7 and MDA-MB-231 cell lines were evaluated by MTT assay. The IC 50 of each cell line was calculated via linear regression. The results showed that the MDA-MB-231 cells (IC 50 =14.521 μМ) were more sensitive than the MCF-7 cells (IC 50 =16.3315 μМ) to 24 h DOX treatment.
The expression of HSP90 before and after treatment with different concentrations of DOX was assayed using western blot analysis. The data from the western blot analysis showed that HSP90 expression decreased in the MCF-7 cells (5 and 10 μM DOX) but increased in the MDA-MB-231 cells (5 and 10 μM DOX) (Figures 1 and 2) . The MCF-7 curve showed that HSP90 expression significantly decreased at a DOX concentration of 10 μM (P < 0.01) (Figure 1-B) . The MDA-MD-231 curve indicated that HSP90 expression significantly increased at DOX concentrations of 5 μМ (*P < 0.05) and 10 μМ (P < 0.01) (Figure  2-B) . The western blotting method was used to detect the HSP90 expression in the MCF-7 cells. Figure 2 (A) shows a sample of blots regarding three independent tests. The data, expressed in means ± standard deviation (n=3), indicated that HSP90 expression significantly declined (P < 0.01) at a DOX concentration of 10 μM, as shown in (B). The representative immunofluorescence images (100X magnification) of the MCF-7 cells are presented in (C). Based on the the optical microscope, cell density decreased after exposure to DOX. Cytoplasmic ventricles and cellular attachments decreased was observed in the cells (D). The western blotting was applied to detect the HSP90 expression in the MDA-MB-231 cells. Figure 2 (A) illustrates a sample of blots regarding three independent tests. The data, expressed as means ± standard deviation (n=3), revealed that the upper expression of HSP90 was significant at DOX concentrations of 5 μМ (P < 0.05) and 10 μМ (P < 0.01), as shown in (B). The representative immunofluorescence images (100X magnification) of the MDA-MB-231 cells are provided in (C). Based on the images seen from the optical microscope, cell density decreased after DOX exposure. Cytoplasmic ventricles and cellular attachments decreased as dosage increased, and cell death was observed in the cells (D).
The immunofluorescence and western blot results showed that the MDA-MB-231 and MCF-7 cells had different levels of HSP90 expression in response to DOX treatment. In the MCF-7 cells, HSP90 expression decreased after DOX treatment. Although expression increased at a DOX concentration of 0.2 μM, the 10 μM dose of DOX significantly reduced such expression. In the MDA-MB-231 cells, HSP90α expression increased after DOX treatment. Expression decreased at a DOX concentration of 0.2 μM but significantly increased at DOX doses of 5 and 10 μM (Figures 1 and 2) . The expression of HSP90 before and after exposure to DOX was determined via immunofluorescence. The findings revealed that HSP90α was expressed in the nucleus and cytoplasm before exposure to DOX but that expression decreased after both cell lines were exposed to DOX. In the MDA-MB-231 cells, the expression of HSP90α decreased even further (Figure 3 ).
Discussion
Breast cancer is a heterogeneous disease with several subtypes, whose current classification may be incomplete or unreliable given that patients with apparently identical types of breast cancer respond differently to the same treatment [2] . Chemotherapy resistance remains an unsolved clinical problem in cancer treatment. Studying different pathways involved in chemotherapy may enable an improved understanding of the mechanism that govern breast cancer and may shed light on more reliable biomarkers. In this research, the expression of HSP90 in MDA-MB-231 and MCF-7 cells before and after treatment with different concentrations of DOX was assayed. In this study, HSP90α protein expression was measured by the immunofluorescence technique in both cell lines before and after exposure to DOX. The toxicity of DOX against the two cell lines was compared using the MTT assay. The comparison of the IC50 values showed that the MDA-MB-231 cells (14.521 μМ) were more sensitive than the MCF-7 cells (16.3315 μМ) to the treatment.
The expression of HSP90α in both cell lines decreased after exposure to DOX. In the MCF-7 cells, DOX decreased the expression of HSP90 in a dose-dependent manner but in the MDA-MB-231 cells, HSP90 expression increased after chemotherapy. In the MDA-MB-231 cells, HSP90 expression decreased with decreasing DOX dose but higher doses induced higher expression. Georgakis et al. tested the effect of an HSP90 inhibitor in anaplastic large cell lymphoma (ALCL) cells. Besides, they inhibited HSP90 without discerning the seemingly different roles of HSP90 isoforms [23] . However, the results of the cited study cannot be directly compared with the present results unless a specific HSP90 isoform inhibitor is used in breast cancer cell lines.
Interestingly, different doses of a chemical sometimes induce opposite responses. For example, in immunofluorescence and western blotting images of MDA-MB-231 cells after exposure to 0.2 μM doxorubicin, the expression of HSP90 initially decreases but its expression increases with increasing drug concentrations (Figure 2) . Also, in MCF-7 cells after exposure to the concentration of 0.2 μM doxorubicin, the expression of HSP90 increased but its expression decreased as the concentration of the drug increased ( Figure 3 ). As observed in the MDA-MB-231 cells, a lower dose of DOX reduced HSP90 expression but a higher dose increased the expression. The most important insight derived from our results was that after chemotherapy, HSP90 expression decreased in the MCF-7 cells but increased in the MDA-MB-231 cells. The reduced expression of HSP90 was expected in general after chemotherapy but its increased expression in the MDA-MB-231 cells is interesting and should be investigated in more details in future studies. The HSP90 serves as a favorable therapeutic target in studying a wide range of cancers. In the early stages of oncogenesis and the maintenance stage of malignant cell phenotypes, high HSP90 expression can be seen [24] . Hence, induction of apoptosis has been shown to be one of the leading approaches in anti-tumor therapy [25, 26] .
In a research, the therapeutic potential of sulforaphane (SFN), an antioxidant derived from broccoli, was evaluated against a chemoresistant cell line (BEAC) in vivo [27] . Immunodeficient mice were injected with BEAC cells, and after the appearance of palpable tumors, the mice were treated with SFN. The SFN induced cell apoptosis, suppressed the expression of multidrug resistance proteins, and reduced tumor volume. The anticancer activity of SFN can induce caspase 8 and p21 and downregulates the HSP90 [28] . In another research, the differential expression of HSP90α and HSP90 in other cancer cells were recorded. A northern blot analysis showed that the levels of HSP90 and HSP90α mRNA in HL60 cells that are resistant to methotrexate or cisplatin were approximately two-to three-fold Journal of Pharmacopuncture 2019; 22[1] :028-034 Figure 3 The expression of HSP90α before and after exposure to Dox was measured. The expression of HSP90α was assessed before exposure to doxorubicin in the nucleus and cytoplasm but decreased after exposure to Dox in both cell lines. The scale bar represents 100 μm.
higher than those in a drug-sensitive parental cell line [29] . In another work, the DOX-resistant colon cancer cell line LoVoDx R expressed a high level of HSP90 constitutively but in a sensitive cell line, no constitutive expression of HSP90 was found [30] . An immunohistochemical study on colorectal cancer patients (26 men and 23 women) before chemotherapy showed the expression of HSP90α and HSP60 in the cytoplasm and the expression of HSP70 in the nucleus of paracancerous tissue; the research also identified the expression of HSP60 and HSP70 in the cytoplasm and the expression of HSP90α in the nucleolus and extracellular matrix of cancerous tissue [31] . In another research, the mRNA expression of HSP60, HSP90α and HSP70 between precancerous and cancerous tissues was compared using RT-PCR. The results showed that HSP60, HSP70 and HSP90α mRNA levels were more highly expressed in cancerous tissue than in precancerous tissue. Western blot analysis confirmed the higher level of these three proteins in cancerous tissue [32, 33] . In another study, HSP90α protein was more highly expressed in cancerous tissue than in non-cancerous tissue [34] . Song et al. (2010) reported that the expression of HSP90 and PI3Ka-P110a was higher in the patients with ER/PR-positive and Her-2-negative breast cancer compared to the patients with ER/PR-negative or Her-2-positive breast cancer. The authors suggested HSP90 and PI3Ka-p110a as molecular prognostic markers for predicting early relapse in patients suffering from breast cancer [35] .
Cell line-specific factors may be part of the reason for the differences in results between the MDA-MB-231 and MCF-7 cells in the current study. MCF-7 cells express estrogen and progesterone receptors whereas MDA-MB-231 cells do not express any of these receptors [19] . One of the major subtypes of breast cancer is that which expresses steroid hormone receptors [36] . Steroid hormone receptors were found to be expressed in 65% and 80% of breast cancer patients before and after menopause, respectively. This means that steroid hormone receptors are expressed, on average, in 75% of breast cancer patients [37] . In another study, the expression of Erk and pErk in MDA-MB-231 and MCF-7 cells was compared after chemotherapy with DOX or docetaxel. The results showed that the MDA-MB-231 and MCF-7 cells responded in completely different ways to the same treatment. The expression of Erk and pErk in the MDA-MB-231 cells expression in the MCF-7 cells increased in a dose-dependent manner after chemotherapy. The expression of pErk decreased in the MDA-MB-231 cells but increased in the MCF-7 cells after docetaxel treatment [38] . The HSP90 isoform-specific interaction with client proteins has also been reported in different studies. Co-immunoprecipitation studies in two different systems showed that both isoforms interacted similarly with different co-chaperones in the HSP90 heterocomplex. Some of the substrates (CKIIB, c-Src, A-Raf and Erk) interacted similarly with both isoforms but after heat shock, they exhibited stronger interaction with HSP90α [39] . One of the HSP90 client proteins is the cellular inhibitor of apoptosis protein-1 (c-IAP1). Inhibition of HSP90 proteins by small chemical molecules and the specific depletion of HSP90 by siRNA results in c-IAP1 auto-ubiquitination and degradation by the proteasome machinery.
The isoform accounts for the chaperone function of HSP90 toward c-IAP1 since the specific HSP90α depletion had no effect on the c-IAP1 percentage [40] . In a study by Dong et al. who investigated MDA-MB-231 breast cancer cell hypoxia in vivo, the inhibition of HSP90α by monoclonal antibody 1G6-D7 increased tumor cell death. They found that the expression of HSP90α secretion is an influential factor in the survival of hypoxic tumor cells [41] . In a study in the presence of B lymphocyte in inflammatory infiltration, estrogen and progesterone receptors disappeared, resulting in the accumulation of HSP90 in the cell and contributing to the stabilization of HER2/neu receptors and the most prominent proteins that led to tumor progression [42] .
Overall, the studies discussed above have shown that HSP90 expression is important and the expression of HSP90 proceeds in a different manner in chemotherapy-resistant cells.
Conclusion
In this study, we observed decreased cellular density in both tested cell types after exposure to DOX. The expression of HSP90α in both cell lines was also decreased after exposure to DOX. The HSP90 expression was reduced in the MCF-7 cells but increased in the MDA-MB-231 cells after DOX treatment. These findings may be attributed to the greater sensitivity of the MDA-MB-231 cells to DOX than the MCF-7 cells or the absence of ERs in MDA-MB-231 cells. Overall, the present results serve as preliminary data for conducting future proof-of-concept studies to explore the role of HSP90 isoforms and estrogen receptors in the sensitivity of breast cancer cells, cancer cell isolates and xenografts to chemotherapeutic agents. Future studies are warranted to test the effect of overexpression of HSP90 on DOX sensitivity in MCF-7 cells, or the effect of knockout of HSP90 on the sensitivity of MDA-MB-231 cells to DOX. Finally, it remains to be explored if HSP90 affects intracellular DOX accumulation in MDA-MB-231 cells and through this potential mechanism regulates the sensitivity of cells to this drug.
